Late-Stage Product Development Pipeline for Differentiated Therapies Treating Central Nervous System Disorders

Orphan drug status in US and Europe

Therapeutic condition: Dravet syndrome, rare and catastrophic form of epilepsy beginning in infancy
Formulation:  Oral liquid, low-dose fenfluramine
Status: Initiated phase 3 clinical studies Q1 2016
Latest data presented on ZX008

Proprietary formulation with a differentiated product profile

Therapeutic condition: Schizophrenia
Formulation:  Once-monthly subcutaneous injection of risperidone
Status: Plans to initiate global development and commercialization partnership discussions in Q4 2015 prior to commencing Phase 3 studies